Singapore markets open in 7 hours 11 minutes
  • Straits Times Index

    3,201.86
    -3.28 (-0.10%)
     
  • S&P 500

    4,566.57
    +21.67 (+0.48%)
     
  • Dow

    35,741.17
    +64.15 (+0.18%)
     
  • Nasdaq

    15,218.97
    +128.77 (+0.85%)
     
  • BTC-USD

    63,053.27
    +2,773.17 (+4.60%)
     
  • CMC Crypto 200

    1,507.11
    +1,264.43 (+521.03%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Gold

    1,807.60
    +11.30 (+0.63%)
     
  • Crude Oil

    83.83
    +0.07 (+0.08%)
     
  • 10-Yr Bond

    1.6320
    -0.0230 (-1.39%)
     
  • Nikkei

    28,600.41
    -204.44 (-0.71%)
     
  • Hang Seng

    26,132.03
    +5.10 (+0.02%)
     
  • FTSE Bursa Malaysia

    1,587.94
    -0.14 (-0.01%)
     
  • Jakarta Composite Index

    6,625.70
    -18.04 (-0.27%)
     
  • PSE Index

    7,211.54
    -78.07 (-1.07%)
     

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., September 01, 2021--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET.

A live webcast of the fireside chat will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005062/en/

Contacts

INVESTOR CONTACT:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com

MEDIA CONTACT:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting